Abbott Laboratories vs. Moleculin Biotech, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ABT | MBRX | |
|---|---|---|
| Market Cap | $174.73 billion | $15.06 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | MBRX | |
|---|---|---|
| P/E Ratio | 32.54 | — |
| Price / Book | 3.38 | — |
| Price / Sales | 3.75 | — |
ABT and MBRX split the valuation factors evenly.
Profitability
| ABT | MBRX | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and MBRX split the profitability factors evenly.
Dividend
| ABT | MBRX | |
|---|---|---|
| Dividend Yield | 2.51% | — |
| Payout Ratio | 81.55 | — |
ABT and MBRX split the dividend factors evenly.
Risk & Sentiment
| ABT | MBRX | |
|---|---|---|
| Short Interest | 0.57% | 7.72% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, MBRX overview, MBRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.